Previous 10 | Next 10 |
Natera's ( NTRA -3.1% ) new lab in Austin will provide 70,000 square foot space and add cutting-edge, automated lab equipment and capabilities. More news on: Natera, Inc., Healthcare stocks news Read more ...
SAN CARLOS, Calif. , June 22, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the expansion of its laboratory facility in Austin, Texas , supporting greater test processing capacity. This ...
Molecular testing services provider Natera ( NTRA +1.3% ) announces the commencement of enrollment in two clinical trials, CIRCULATE-Japan and BESPOKE CRC, evaluating clinical outcomes of its Signatera molecular residual disease (MRD) test in patients with resectable (Stages II - IV...
SAN CARLOS, Calif. , June 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and BESPOKE CRC trials, with both studies experiencing strong interest from centers ac...
SAN CARLOS, Calif. , June 17, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, filed suit today against Progenity, Inc. for infringing six patents: U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,...
Progenity ( PROG ) has filed a prospectus for its IPO of ~6.7M common shares at $14 - 16 per share. Gross proceeds should be ~$100M (midpoint). More news on: Progenity, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Healthcare stocks news, IPO News, , ...
Quick Take Progenity ( PROG ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The firm is commercializing molecular testing products to maximize the ability to personalize disease treatments. PROG is dealing with the temporary ...
SAN CARLOS, Calif. , June 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance results from the Prospera donor-derived cell-free DNA (dd-cfDNA) transplan...
SAN CARLOS, Calif. , May 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its Prospera donor-derived cell-free DNA (dd-cfDNA) transplant assessment test at the 2020 Amer...
SAN CARLOS, Calif. , May 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and its collaborators will present new data demonstrating the clinical validity and utility of its personalized molecular residual disease (MR...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...